Lipid Drug Formulation via Coacervation for Low L/D Ratios
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid-based drug delivery systems for inhalation face challenges in achieving low lipid-to-drug (L/D) ratios, leading to saturation effects and limited administration and effectiveness, particularly in chronic use for pulmonary infections.
Innovation Solution
The use of coacervation techniques to create liposomes with a low L/D ratio by forming drug coacervates that induce lipid bilayer formation, resulting in higher drug entrapment and lower L/D ratios, allowing for higher drug delivery rates and prolonged therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional lipid-based formulations are used, then drug delivery is achieved, but the L/D ratio is high causing saturation effects and limited administration
Solution Approach 1:
The patent applies parameter changes by modifying the L/D ratio from conventional high values to low values (0.01-0.5), and by changing the preparation method parameters (pH, ionic strength, temperature) to achieve coacervation. This allows higher drug loading while minimizing lipid requirements, directly resolving the contradiction between drug delivery rate and lipid load.
Solution Approach 2:
The patent creates composite materials by forming coacervates - complex associations between charged polymers and oppositely charged ions/molecules. This composite structure enables highly efficient drug entrapment within the coacervate phase, allowing low L/D ratios while maintaining high drug delivery rates.
2Quantity of substance
If L/D ratio is reduced to minimize lipid load, then saturation effects are avoided, but formulation preparation becomes more challenging
Solution Approach 1:
The patent applies preliminary action by pre-forming coacervates before mixing with lipids. The coacervate formation step creates a pre-concentrated drug reservoir that then incorporates into liposomes, simplifying the overall process of achieving low L/D ratios while ensuring high drug entrapment efficiency.
Solution Approach 2:
The patent uses coacervates as an intermediary structure between the drug and lipid components. The coacervate phase acts as a mediator that facilitates efficient drug-lipid interaction and entrapment, making the formulation process more controllable and reproducible despite the challenging low L/D ratio requirements.
3Manufacturing precision
If coacervation techniques are used to achieve low L/D ratios, then drug entrapment increases, but process complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the formulation process into distinct stages: coacervate formation, lipid mixing, and final formulation. This segmentation allows each step to be optimized independently, achieving high drug entrapment efficiency (70-95%) while managing process complexity through modular, controllable steps.
4Productivity
If high drug delivery rates are achieved, then therapeutic effect is enhanced, but lipid clearance threshold is reached faster
Solution Approach 1:
The patent applies continuity of useful action through sustained release mechanisms. The coacervate-lipid formulation provides continuous drug release over extended periods, maintaining therapeutic levels while allowing less frequent dosing. This resolves the contradiction by enabling high total drug delivery rates while extending the dosing interval through controlled release kinetics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the formulation of lipid-based drug formulations with L/D ratios of 0.40-0.49:1, achieving enhanced drug delivery and sustained release in the lung, effectively treating pulmonary infections with reduced dosing frequency and increased therapeutic index.
Implementation Method 1
mixing an aqueous solution of the active agent with the lipid solution to form a coacervate
Implementation Method 2
The organic solvent is ethanol
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.